Get started
PHARMING GROUPPHARMING GROUPPHARMING GROUP

PHARMING GROUP

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

PHARM chart


Full chart

PHARM upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪480.98 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.0150 EUR
Net income (FY)
‪−10.95 M‬ EUR
Revenue (FY)
‪274.76 M‬ EUR
Shares float
‪667.46 M‬
Beta (1Y)
1.52

About PHARMING GROUP


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Fabrice Chouraqui
Website
pharming.com
Headquarters
Leiden
Founded
2019
ISIN
NL0010391025
FIGI
BBG000D2BVP2
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

PHARM news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

PHARM highest yielding bonds


XS276301888
PHARMING GRP 24/29 CV
Yield to maturity
6.78%
Maturity date
Apr 25, 2029

See all PHARM bonds 


Check out other big names from the same industry as PHARM.

Frequently Asked Questions


The current price of PHARM is 0.7010 EUR — it has decreased by −0.85% in the past 24 hours. Watch PHARMING GROUP stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange PHARMING GROUP stocks are traded under the ticker PHARM.
PHARM stock has fallen by −7.28% compared to the previous week, the month change is a −14.51% fall, over the last year PHARMING GROUP has showed a −26.98% decrease.
We've gathered analysts' opinions on PHARMING GROUP future price: according to them, PHARM price has a max estimate of 3.56 EUR and a min estimate of 1.38 EUR. Watch PHARM chart and read a more detailed PHARMING GROUP stock forecast: see what analysts think of PHARMING GROUP and suggest that you do with its stocks.
PHARM reached its all-time high on Jun 29, 2005 with the price of 50.0245 EUR, and its all-time low was 0.0585 EUR and was reached on Apr 24, 2013. View more price dynamics on PHARM chart.
See other stocks reaching their highest and lowest prices.
PHARM stock is 1.43% volatile and has beta coefficient of 1.52. Track PHARMING GROUP stock price on the chart and check out the list of the most volatile stocks — is PHARMING GROUP there?
Today PHARMING GROUP has the market capitalization of ‪476.90 M‬, it has increased by 3.15% over the last week.
Yes, you can track PHARMING GROUP financials in yearly and quarterly reports right on TradingView.
PHARMING GROUP is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
PHARM earnings for the last quarter are 0.0048 EUR per share, whereas the estimation was 0.0018 EUR resulting in a 163.16% surprise. The estimated earnings for the next quarter are −0.0023 EUR per share. See more details about PHARMING GROUP earnings.
PHARMING GROUP revenue for the last quarter amounts to ‪89.55 M‬ EUR, despite the estimated figure of ‪78.49 M‬ EUR. In the next quarter, revenue is expected to reach ‪62.61 M‬ EUR.
PHARM net income for the last quarter is ‪3.47 M‬ EUR, while the quarter before that showed ‪−941.24 K‬ EUR of net income which accounts for 468.52% change. Track more PHARMING GROUP financial stats to get the full picture.
No, PHARM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PHARMING GROUP EBITDA is ‪364.92 K‬ EUR, and current EBITDA margin is 2.48%. See more stats in PHARMING GROUP financial statements.
Like other stocks, PHARM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PHARMING GROUP stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PHARMING GROUP technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PHARMING GROUP stock shows the strong sell signal. See more of PHARMING GROUP technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.